Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 92Neoplasm Metastasis 10Neoplasms 9Breast Diseases 4Advanced Breast Cancer 3Recurrence 2Neoplasms by Site 2Carcinoma, Renal Cell 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Post Menopausal Women With Early Breast Cancer 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Multiple Endocrine Neoplasia Type 1 1Mammary Neoplasms, Animal 1Lymphoma 1Lung Neoplasms 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1Kidney Neoplasms 1Invasive Early Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1

Interventions

exemestane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Invasive Early Breast Cancer × exemestane × Clear all
NCT01121549 2014-01-22

A Non-Interventional Study With AromasinĀ® As Adjuvant Treatment Of Invasive Early Breast Cancer

Pfizer

Terminated
378 enrolled 16 charts
Breast

Invasive Early Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚔